Measles cases are on the rise, mostly among unvaccinated people. Know the symptoms
The Texas Department of State Health Services reported Tuesday that an outbreak in northwest Texas escalated from two cases among unvaccinated children in Gaines County to 58 cases across five counties. The majority of the infected children were either unvaccinated or had an unknown vaccination status.
On Feb. 14, New Mexico officials declared an outbreak in Lea County, just across state lines from Gaines County. Three residents tested positive for measles during the week.
Centers for Disease Control and Prevention data through Feb. 6 showed five states with measles cases: Alaska, Georgia, New York City, Rhode Island and Texas.
Measles outbreaks are low but not gone
The last major outbreak of measles in the U.S. occurred six years ago when 22 outbreaks led to 1,249 cases from Jan. 1 to Oct. 1. According to the CDC, the 2019 outbreak was the highest in a single year since 1992 – eight years before measles was declared eliminated in the U.S.
Unable to view our graphics? Click here to see them.
Where states allow vaccination exemptions
Nationwide, childhood immunization rates against serious diseases like measles are declining as more parents request non-medical exemptions from recommended vaccinations, according to the CDC.
In the 2023–2024 school year, more than three-quarters of states had kindergartener MMR (measles, mumps and rubella) vaccination coverage rates below the CDC's Healthy People target of 95%. Of note, even states with high immunization rates may have pockets of unvaccinated people.
More:Measles continues to spread as Texas outbreak rises to 48 cases: Here's what to know
Given that measles is extremely contagious and can cause severe complications including pneumonia and brain swelling, the drop in vaccination rates is concerning. The measles, mumps and rubella (MMR) vaccine is 97% effective at preventing measles, and the CDC advises people be vaccinated twice.
What are measles symptoms?
According to the CDC, measles symptoms appear seven to 14 days after contact with the virus and typically include high fever, cough, runny nose and watery eyes. Measles rash appears three to five days after the first symptoms.
Other signs and symptoms of measles include:
Koplik's spots, tiny white spots that may appear inside the mouth two to three days after symptoms begin
Small raised bumps may also appear on top of the flat red spots (the spots may become joined together as they spread from the head to the rest of the body)
When the rash appears, a person's fever may spike to more than 104 degrees
CONTRIBUTING John Bacon and Jim Sergent
This story was updated to add new information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Cutting-edge Diagnostic Technologies Transforming $6.4 Billion Landscape
The U.S. Alzheimer's disease diagnostics market, valued at USD 3.53 billion in 2024, is projected to grow at a CAGR of 10.6% from 2025-2030. Growth is driven by rising Alzheimer's prevalence and advanced diagnostics like FDA-approved blood tests, improving early detection and care planning. U.S. Alzheimer's Disease Diagnostics Market Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "U.S. Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Technique (Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests), By Type, By End-use, And Segment Forecasts, 2025 - 2030" report has been added to U.S. Alzheimer's disease diagnostics market was valued at USD 3.53 billion in 2024 and is expected to grow at a CAGR of 10.6% from 2025 to 2030 This growth is driven by the rising prevalence of Alzheimer's disease and increasing emphasis on early and accurate diagnosis. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 6.7 million older adults in the U.S. were living with Alzheimer's disease in 2024, a number projected to nearly double by 2060. The growing prevalence of the disease prompted government and private healthcare bodies to invest heavily in advanced diagnostic technologies such as PET imaging, cerebrospinal fluid biomarkers, and blood-based diagnostics. The growth of the U.S. Alzheimer's disease diagnostics market is due to the recent regulatory approval of advanced, non-invasive diagnostic technologies. The U.S. FDA granted marketing clearance for the first in vitro diagnostic device that utilizes a blood test to support the diagnosis of Alzheimer's disease. The Lumipulse G pTau217/b-Amyloid 1-42 Plasma Ratio is specifically intended for the early detection of amyloid plaque accumulation, a hallmark of Alzheimer's pathology, in adult patients aged 55 years and older who are exhibiting clinical signs and symptoms consistent with cognitive development represents a major advancement in Alzheimer's diagnostics, significantly lowering access barriers by providing a cost-effective and minimally invasive alternative to PET scans and lumbar punctures, which often carry procedural risks. The FDA highlighted that this approval makes it easier and potentially more accessible for U.S. patients earlier in the disease. It underscores the test's value in facilitating timely intervention and clinical decision-making in the early stages of Alzheimer's disease increasing rate of dementia diagnosis among older adults is driving the growth of the U.S. Alzheimer's diagnostics market. According to the 2022 National Health Interview Survey by the CDC, approximately 4% of individuals aged 65 and older have been diagnosed with dementia, with this figure rising to 13% among those aged 85 and above. This growth is primarily attributed to longer life expectancy, enhanced awareness, and improved diagnostic practices across clinical settings. The rising need for scalable, accurate diagnostic solutions to support early detection, appropriate intervention, and optimized care planning. Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $3.53 Billion Forecasted Market Value (USD) by 2030 $6.43 Billion Compound Annual Growth Rate 10.6% Regions Covered United States Competitive Landscape GE HealthCare Siemens Healthineers AG Canon Medical Systems Corporation Cerveau Technologies, Inc. Neurovision Imaging, Inc. Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. Quanterix Corporation Alzheon Inc. NanoSomiX, Inc. DiamiR Biosciences Company Overview Financial Performance Diagnostic Technique Portfolio Recent Developments/ Strategic Initiatives U.S. Alzheimer's Disease Diagnostics Market Report SegmentationDiagnostic Technique Outlook (Revenue, USD Million, 2018 - 2030) Biomarkers CSF Biomarkers Blood-Based Biomarkers Imaging Diagnostic Techniques Genetic Testing Cognitive Assessment Tests Type Outlook (Revenue, USD Million, 2018 - 2030) Triage Diagnosis Screening End Use Outlook (Revenue, USD Million, 2018 - 2030) Hospitals Diagnostic Laboratories Academic & Research Institutes For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Alzheimer's Disease Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
New York Times
2 hours ago
- New York Times
C.D.C. Ties 85 Cases of THC-Related Symptoms to Wisconsin Restaurant
Federal health officials warn of the possibility of 'mass THC intoxication events' from food, in a report that explored how at least 85 people were sickened last year after eating at a restaurant that mistakenly used THC-infused oil to prepare dough. The report, which was released on Thursday by the Centers for Disease Control and Prevention, documented cases that surfaced after patrons ate at the restaurant, Famous Yeti's Pizza, in Stoughton, Wis. THC, or tetrahydrocannabinol, is a psychoactive ingredient found in many cannabis products. From Oct. 22 to Oct. 24 last year, dozens of people, up to 91 years old, experienced symptoms that included dizziness, sleepiness and anxiety, after eating pizza, garlic bread, cheese bread and sandwiches at Famous Yeti's, the C.D.C. said. The restaurant is in a building that shares a commercial kitchen with other businesses, including a state-licensed vendor that makes edible THC products. An investigation began after local emergency services reported to public health officials on Oct. 24 that seven people were transported to a hospital for dizziness, sleepiness and anxiety since Oct. 22, according to the C.D.C. All seven people had eaten at the same restaurant, the report said. Carbon monoxide tests at the restaurant, as well as at the homes of two people who experienced symptoms, were negative, according to the C.D.C. report. All seven people were treated in an emergency department for THC intoxication, the C.D.C. said. Want all of The Times? Subscribe.
New York Times
2 hours ago
- New York Times
What Happens When Doctors Can't Trust the Government?
The other day I was talking to one of my patients about her vaccinations, and I noticed that she hadn't had a Covid-19 vaccine since the early days of the pandemic. 'The virus has changed so much since then,' I told her, 'so we recommend that you get the current vaccine——' And then I stopped dead in my tracks, the words 'we recommend' lingering in the air. This is how I'd always phrased these types of recommendations, but I was suddenly unsure of who the 'we' was. Up until recently, it meant a medical community that included not just my health care colleagues, but also the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health, respected medical journals and the research community. It's not remotely feasible for practicing clinicians to review every medical study out there, so we rely on trusted colleagues and institutions with the relevant expertise to help guide us. The 'we' suddenly rang hollow. The institutions I trusted to be deliberative and evidence-based sources of knowledge that extend my medical abilities are no longer that. In the first Trump administration, despite relentless attacks from the president, the nation's public health institutions remained largely intact, if wearied. But the plunder of the second Trump administration has disemboweled them and installed fox-guarding-the-henhouse leadership. Medical professionals can no longer fully trust federal health guidance, and our patients are the ones who will suffer the most. For most of my colleagues and me, the C.D.C. and the N.I.H. were the medical Mount Olympus, the towering pillars of medical authority. Contrary to right-wing portrayals, these were not dictatorial authorities. These were earned authorities, comprising our best, brightest and most dedicated peers. The formidable talents of these doctors and scientists would have commanded enviable salaries had they taken jobs in industry, but they chose the public sector instead — something that we clinicians were forever grateful for. Were there egos, missteps and shortcomings? Sure. But by and large, the people I met who worked for the C.D.C. or N.I.H. were brilliant and rigorous, and cared passionately about the science they were pursuing. While there are some doctors who viewed our public health institutions with disdain — some of them now are running these very organizations — most practicing physicians relied heavily on them to deliver the best care possible to their patients, despite occasional quibbles. What a relief, I always felt, that there were people organizing the things I can't do — testing new treatments, conducting population studies, keeping tabs on worldwide diseases, issuing guidelines and more. Want all of The Times? Subscribe.
